(Q41926859)

English

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

scientific article published on January 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 October 2017

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group (English)

1 reference

Europe PubMed Central

14 October 2017

hydroxychloroquine

1 reference

based on heuristic

inferred from title

author name string

E Tsakonas

1

1 reference

Europe PubMed Central

14 October 2017

L Joseph

2

1 reference

Europe PubMed Central

14 October 2017

J M Esdaile

3

1 reference

Europe PubMed Central

14 October 2017

D Choquette

4

1 reference

Europe PubMed Central

14 October 2017

J L Senécal

5

1 reference

Europe PubMed Central

14 October 2017

A Cividino

6

1 reference

Europe PubMed Central

14 October 2017

D Danoff

7

1 reference

Europe PubMed Central

14 October 2017

C K Osterland

8

1 reference

Europe PubMed Central

14 October 2017

C Yeadon

9

1 reference

Europe PubMed Central

14 October 2017

C D Smith

10

1 reference

Europe PubMed Central

14 October 2017

publication date

1 January 1998

1 reference

Europe PubMed Central

14 October 2017

1 reference

Europe PubMed Central

14 October 2017

7

1 reference

Europe PubMed Central

14 October 2017

80-85

1 reference

Europe PubMed Central

14 October 2017

2

1 reference

Europe PubMed Central

14 October 2017

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Antimalarials in the management of discoid and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Measuring health status in arthritis. The arthritis impact measurement scales.

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1191%2F096120398678919778

21 January 2018

Identifiers

10.1191/096120398678919778

1 reference

Europe PubMed Central

14 October 2017

1 reference

Europe PubMed Central

14 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41926859&oldid=1929947207"